Viewing Study NCT00946257


Ignite Creation Date: 2025-12-24 @ 6:57 PM
Ignite Modification Date: 2026-01-22 @ 6:31 AM
Study NCT ID: NCT00946257
Status: COMPLETED
Last Update Posted: 2017-06-01
First Post: 2009-07-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Subcutaneous Administration of Otelixizumab to T1DM Patients
Sponsor: GlaxoSmithKline
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module